HTT and Huntington disease: We therefore tested its effect in other HD models and discovered that SB202190 treatment was able to reduce Htt levels in a Mapk11-dependent manner in primary striatal neurons cultured from the KI HD mice (HdhQ7/Q140) (Figure 4D), further confirming the kinase-activity dependence and providing an entry point for HD drug discovery.